Drug intelligence / Profile preview

5-(4-Morpholin-4-Yl-Phenylsulfanyl)-2,4-Quinazolinediamine

Development stage: Unknown
Modality: Small Molecules

Overview

5-(4-Morpholin-4-Yl-Phenylsulfanyl)-2,4-Quinazolinediamine is an experimental small molecule compound belonging to the class of phenylmorpholines. It features a quinazoline core substituted with a morpholine-containing phenylthio group. The compound has not been approved for any therapeutic use and there are no reported clinical trials or indications. Its mechanism of action and biological targets have not been characterized in publicly available sources[1][2][4].

Beyond the preview

Go deeper on 5-(4-Morpholin-4-Yl-Phenylsulfanyl)-2,4-Quinazolinediamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 5-(4-Morpholin-4-Yl-Phenylsulfanyl)-2,4-Quinazolinediamine.

Explore the full profile